Cesium-131 Collagen Tiles Improve Local Control in Recurrent Meningioma

The Challenge of Refractory Aggressive Meningiomas

Meningiomas represent the most frequent primary intracranial tumor, yet the management of aggressive subtypes remains a significant clinical hurdle for neurosurgeons and oncologists [1, 2]. While maximal surgical resection is the established first-line intervention, World Health Organization Grade 2 and 3 lesions frequently recur, often after patients have already reached the limits of external beam radiation therapy [3, 4]. For these refractory cases, systemic options such as chemotherapy or targeted molecular agents have historically yielded only marginal success, leaving a critical void in effective salvage protocols [5]. Brachytherapy, a technique involving the internal placement of radioactive sources, offers a theoretical advantage by delivering high-dose radiation directly to the resection cavity while minimizing exposure to previously irradiated healthy brain tissue [6, 7]. A recent prospective trial now provides long-term evidence on the efficacy and safety of this targeted strategy in patients with recurrent disease, offering clinicians a potential new tool for managing treatment-resistant tumors.

Trial Design and Patient Characteristics

To evaluate the efficacy of a combined surgical and radiotherapeutic approach for difficult-to-treat intracranial tumors, researchers conducted a prospective, nonrandomized, single-center trial between June 2013 and January 2018. The study cohort consisted of 27 patients with 29 recurrent aggressive meningiomas, a population often limited by prior treatment exposures. Participants had a median age of 66 years (ranging from 37 to 82 years). This demographic reflects the typical clinical presentation of advanced meningioma, where patients have often undergone multiple prior interventions before requiring salvage therapy.

At the time of enrollment, tumors were classified according to World Health Organization criteria to confirm their aggressive nature. The majority of the cases, 26 out of 29 (90%), were identified as grade 2, while 2 cases (7%) were grade 3 and 1 case (3%) was grade 1. To address these lesions, all patients underwent maximal safe resection followed immediately by the placement of modular, biocompatible cesium-131 tiles. This technique, known as cesium-131 collagen tile brachytherapy, allows for the precise delivery of radiation to the operative bed to target residual microscopic disease. The collagen carrier provides a physical buffer for the radioactive source, a feature highly relevant for neurosurgeons seeking to maximize local tumor control without damaging adjacent critical brain structures.

Five-Year Local Control and Radiographic Outcomes

The researchers monitored patients using serial imaging to assess the efficacy of the intervention over an extended period, reporting a median radiographic follow-up of 34.8 months (range 0.0 to 70.9 months). To ensure clinical precision in evaluating the surgical site, the study defined local progression as radiographic evidence of tumor recurrence within 1.5 centimeters of the operative bed. This specific margin allows clinicians to distinguish between a failure of the local treatment and the development of distant intracranial disease.

The longitudinal data demonstrated a substantial difference in tumor stability when compared to the patients' previous treatment outcomes at the exact same anatomical site. At the 48-month mark, local control was maintained in 73% of cases following resection plus cesium-131 collagen tile brachytherapy, whereas prior treatments at the same site had achieved only a 21% control rate. This divergence remained evident as the study reached the five-year threshold. By 60 months, the local control rate was 48% for the study intervention, contrasted with a 17% rate observed with previous therapeutic attempts.

Statistical analysis confirmed the clinical significance of these findings, yielding a hazard ratio of 0.145 (p < 0.001) for local control. A hazard ratio of this magnitude indicates an 85.5% reduction in the relative risk of local progression for patients receiving the collagen tiles compared to their own prior therapies. For practicing oncologists and surgeons, this suggests that integrating cesium-131 tiles into the surgical cavity provides a significantly more durable response than standard salvage therapies previously utilized for this patient population.

Safety Profile and Complication Management

The safety profile of combining surgical resection with cesium-131 collagen tile brachytherapy is a critical consideration for clinicians managing recurrent disease, particularly given the history of prior treatments in this patient population. In this study, surgery-related complications occurred in 4 cases (14%) out of the 29 treated tumors. When analyzing the timing and nature of these events, the researchers identified that early postoperative infection occurred in 1 case (3%). The remaining surgical complications were characterized by delayed wound breakdown and infection, which occurred in 3 cases (10%). These findings suggest that while the majority of patients tolerate the procedure well, vigilant postoperative monitoring for wound integrity is necessary, particularly in the delayed phase following the implantation of the radioactive tiles.

Beyond direct surgical risks, the study also monitored for adverse effects related to the localized delivery of isotopes within the resection cavity. Radiation brain injury (damage to the surrounding healthy brain tissue caused by ionizing radiation) occurred in 4 cases (14%). This incidence rate is an important metric for clinicians to discuss with patients when weighing the benefits of local tumor control against potential neurotoxicity. However, the clinical impact of these events was mitigated by successful intervention, as all 4 cases of radiation brain injury resolved with medical therapy. This complete resolution indicates that the radiation-induced changes associated with cesium-131 tiles are manageable within a standard clinical framework, providing a favorable risk-to-benefit ratio for patients with aggressive, recurrent meningiomas who have exhausted other therapeutic options.

References

1. Hsieh AL, Bi WL, Ramesh V, Brastianos PK, Plotkin SR. Evolving concepts in meningioma management in the era of genomics. Cancer. 2024. doi:10.1002/cncr.35279

2. Yarabarla V, Mylarapu A, Han T, McGovern SL, Raza SM, Beckham TH. Intracranial meningiomas: an update of the 2021 World Health Organization classifications and review of management with a focus on radiation therapy. Frontiers in Oncology. 2023. doi:10.3389/fonc.2023.1137849

3. Mooney MA, Essayed WI, Patel V, Devlin PM, Al‐Mefty O. Brachytherapy as Salvage Treatment for Meningioma With Malignant Progression After Exhausting Other Treatment Options: 2-Dimensional Operative Video. Operative Neurosurgery. 2022. doi:10.1227/ons.0000000000000129

4. Pacult MA, Przybylowski CJ, Raza SM, DeMonte F. Surgical Management of High-Grade Meningiomas. Cancers. 2024. doi:10.3390/cancers16111978

5. Yuen C, Zheng M, Saint-Germain M, Kamson D. Meningioma: Novel Diagnostic and Therapeutic Approaches. Biomedicines. 2025. doi:10.3390/biomedicines13030659

6. Choi M, Zabramski JM. Re-Irradiation Using Brachytherapy for Recurrent Intracranial Tumors: A Systematic Review and Meta-Analysis of the Literature. Cureus. 2020. doi:10.7759/cureus.9666

7. Garcia MA, Turner AC, Brachman D. The role of GammaTile in the treatment of brain tumors: a technical and clinical overview. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-023-04523-z